B. Cheson, B. Pfistner, and M. Juweid, Revised Response Criteria for Malignant Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.579-586, 2007.
DOI : 10.1200/JCO.2006.09.2403

M. Juweid, S. Stroobants, and O. Hoekstra, Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.571-578, 2007.
DOI : 10.1200/JCO.2006.08.2305

S. Barrington, N. Mikhaeel, and L. Kostakoglu, Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, Journal of Clinical Oncology, vol.32, issue.27, pp.3048-3058, 2014.
DOI : 10.1200/JCO.2013.53.5229

Y. Kasamon and R. Wahl, FDG PET and risk-adapted therapy in Hodgkin?s and non-Hodgkin?s lymphoma, Current Opinion in Oncology, vol.20, issue.2, pp.206-219, 2008.
DOI : 10.1097/CCO.0b013e3282f5123d

Y. Kasamon, R. Wahl, and H. Ziessman, Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning, Biology of Blood and Marrow Transplantation, vol.15, issue.2, pp.242-248, 2009.
DOI : 10.1016/j.bbmt.2008.11.026

L. Sehn, E. Hardy, and K. Gill, Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC) [abstract], Blood, vol.124, p.392, 2014.

M. Hertzberg, M. Gandhi, and J. Trotman, Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14, Haematologica, vol.102, issue.2, pp.356-363, 2017.
DOI : 10.3324/haematol.2016.154039

U. Duehrsen, H. ¨. , A. , M. ¨. , and S. , Positron emission tomography (PET) guided therapy of aggressive lymphomas?a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial) [abstract], Blood, vol.124, p.391, 2014.

H. Lanic, S. Mareschal, and F. Mechken, Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma, Leukemia & Lymphoma, vol.116, issue.1, pp.34-42, 2012.
DOI : 10.1200/JCO.2010.30.0368
URL : https://hal.archives-ouvertes.fr/hal-00673375

L. Ceriani, M. Martelli, and P. Zinzani, Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma, Blood, vol.126, issue.8, pp.950-956, 2015.
DOI : 10.1182/blood-2014-12-616474

C. Pinnix, B. Dabaja, and M. Ahmed, Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography, International Journal of Radiation Oncology*Biology*Physics, vol.92, issue.1, pp.113-121, 2015.
DOI : 10.1016/j.ijrobp.2015.02.006

M. Sasanelli, M. Meignan, and C. Haioun, Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.50, issue.Suppl 1, pp.2017-2022, 2014.
DOI : 10.2967/jnumed.108.057182
URL : https://hal.archives-ouvertes.fr/hal-01141151

F. Scherer, D. Kurtz, and A. Newman, Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA, Science Translational Medicine, vol.492, issue.31, pp.364-155, 2016.
DOI : 10.1038/nature11606

G. Jerusalem, Y. Beguin, and M. Fassotte, Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma, Haematologica, vol.85, issue.6, pp.613-618, 2000.

C. Haioun, E. Itti, and A. Rahmouni, [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome, Blood, vol.106, issue.4, pp.1376-1381, 2005.
DOI : 10.1182/blood-2005-01-0272

N. Mikhaeel, M. Hutchings, P. Fields, O. Doherty, M. Timothy et al., FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma, Annals of Oncology, vol.16, issue.9, pp.1514-1523, 2005.
DOI : 10.1093/annonc/mdi272

S. Querellou, F. Valette, and C. Bodet-milin, FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin???s lymphoma and Hodgkin???s disease, Annals of Hematology, vol.23, issue.Suppl 2, pp.759-767, 2006.
DOI : 10.1007/BF00833385

C. Fruchart, O. Reman, L. Stang, and N. , Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study, Leukemia & Lymphoma, vol.30, issue.12, pp.2547-2557, 2006.
DOI : 10.1007/s00259-003-1333-8

J. Dupuis, E. Itti, and A. Rahmouni, Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma

R. Carr, S. Fanti, and D. Paez, Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma, Journal of Nuclear Medicine, vol.55, issue.12, pp.1936-1944, 2014.
DOI : 10.2967/jnumed.114.145326

D. Yang, J. Min, and H. Song, Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma, European Journal of Cancer, vol.47, issue.9
DOI : 10.1016/j.ejca.2010.12.027

I. Micallef, M. Maurer, and G. Wiseman, Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma, Blood, vol.118, issue.15, pp.4053-4061, 2011.
DOI : 10.1182/blood-2011-02-336990
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204728

P. Zinzani, L. Gandolfi, and A. Broccoli, Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma, Cancer, vol.15, issue.5, pp.1010-1018, 2011.
DOI : 10.1016/j.bbmt.2008.11.026

C. Yoo, D. Lee, and J. Kim, Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP, Annals of Hematology, vol.107, issue.7, pp.797-802, 2011.
DOI : 10.1002/cncr.22276

L. Swinnen, H. Li, and A. Quon, Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404), British Journal of Haematology, vol.117, issue.1, pp.56-65, 2015.
DOI : 10.1002/cncr.25579
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696544

P. Pregno, A. Chiappella, and M. Belì-o, Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP, Blood, vol.119, issue.9, pp.2066-2073, 2012.
DOI : 10.1182/blood-2011-06-359943

N. Nols, N. Mounier, and S. Bouazza, Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma, Leukemia & Lymphoma, vol.90, issue.1, pp.773-780, 2014.
DOI : 10.1102/1470-7330.2013.0006